QVance was founded in 2024 and is the daughter company of NextCell Pharma AB. Based in Huddinge in the south of Stockholm, Sweden, the company has evolved out of a recognition for the need for quality control analytical service provision for cell and gene therapy in the Nordics.
QVance leadership team have a combined knowledge of over 40 years in cell and gene therapy development. Together we have developed a company vision and mission that is solution driven and customer and product centric.
Chairman of the Board
Dr Svahn was a founding member of NextCell Pharma and has worked in the cell and gene therapy space for over 10 years. He is a serial entrepreneur having founded Cellaviva, a private stem cell bank and NextCell Pharma, QVance’s parent company, working in cell therapy drug development for autoimmune and inflammatory disorders. Mathias is currently employed as CEO for NextCell Pharma and has previously worked in the life science sector within academia at Karolinska Institutet, and in industry as a Medical Manager at Roche.
Board Member
Dr Davies has over 20 years experience working in cell therapy in academia and industry. Lindsay has worked with process and product development, as well as establishing critical quality attributes for cell therapies in early and late phase clinical trials. Lindsay has worked with regulatory considerations for multiple advanced therapy drug products and investigational medicinal products within Europe.
Lindsay is currently the Chief Scientific Officer for NextCell Pharma and is the European Regional Secretary for the International Society of Cell and Gene Therapy.
Chief Financial Officer and Board Member
With over 30 years experience working in the financial sector, and a specialism in life sciences Patrik is responsible for financial operations at QVance and a member of the Board of Directors.